Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Andriukaitis: Supporting drug innovation is 'the only way'

October 10, 2017, EurActiv

Peter Bogaert is quoted in a EurActiv article regarding EU Commissioner for Health and Food Safety Vytenis Andruikaitis' remarks in support of drug innovation. "The incentives which are built in the pharmaceutical regime and especially the SPCs and the regulatory exclusivity aim to work as a stimulus to develop new products in order to basically continue the innovation in the long term," Bogaert says. He notes that there might be models where one has a more fine-tuned approach to the prices but one should not attack the innovation system purely in order to get cheaper products because then "you are undermining the incentives for new products and this reduces the level of innovation in the industry." Bogaert adds, "The IP aims to give certain exclusivity rights, it's a stimulus to innovate and develop new products and the basic idea is that you can get a good financial return on innovation efforts."

Share this article: